ABSTRACT
Objective@#To investigate the effects of luteolin on the invasion and migration of the human tongue squamous carcinoma cell line SCCl5. @*Methods @#SCC15 cells were treated with various concentrations of luteolin (5, 10, 15, 20, 40 and 60 μg/mL) for 24, 48 and 72 h. The MTT assay was then carried out to estimate the proliferation of SCC15 cells treated with various concentrations of luteolin. SCC15 cells were treated with various concentrations of luteolin (1, 5 and 10 μg/mL), and the migration of SCC15 cells was examined in wound healing assays. SCC15 cells were treated with various concentrations of luteolin (5 and 10 μg/mL) for 24 h, and the migration and invasion of the cells were examined in Transwell migration/invasion assays. SCC15 cells were treated with various concentrations of luteolin (10, 20 and 40 μg/mL) for 24 h, and the conditioned medium was collected. The levels of the gelatinases matrix metalloproteinases-2 and -9 (MMP-2, MMP-9) in the conditional medium were detected by gelatin zymography assays.@*Results @#The MTT assay showed that luteolin had a substantial inhibitory effect on the proliferation of SCC15 cells in a concentration- and time-dependent manner (P < 0.01). The migration, invasion and proliferation of the SCCl5 cell lines were significantly lower after treatment with luteolin than in the control. The numbers of migrating and invading SCCl5 cells were 340.00 ± 22.94, 52.67 ± 6.94 and 6.57 ± 0.80 versus 85.67 ± 5.18, 39.67 ± 4.63 and 2.67 ± 0.29, respectively (P < 0.01). The enzyme activities of MMP-2 and MMP-9 decreased significantly in response to luteolin treatment in a concentration-dependent manner (P < 0.01). @*Conclusion @# Luteolin inhibited the invasion and migration of SCC15 cells by reducing the activities of MMP-2 and MMP-9.
ABSTRACT
@#Objective To detect the difference of periostin expression in small cell lung cancer (SCLC) cell, and explore its effect on chemoresistance of SCLC patients. Methods The expression of periostin in mRNA and protein was detected by RT-PCR and Western blot analysis in SCLC H69 and multidrug resistant strain H69AR. The expression of periostin was up-regulated by recombinant plasmid-periostin in H69 cell. The survival rate in the transfected group was different from that of the negative control group and uninterrupted group. Results The expression of periostin mRNA and protein in the sensitive strain H69 was lower than that of the multidrug resistant strain H69AR (P<0.05). The recombinant periostin-plasmid was transfected into H69 cells and at the same concentration of chemotherapeutic drugs (cisplatin, etoposide) the survival rate increased significantly (P<0.05). The positive expression rate of periostin in SCLC tissues was 67.44%, and the sensitivity of the chemotherapy group was lower than that of the drug resistant group (P<0.05). Conclusion The expression of periostin in SCLC cell H69 is significantly lower than that of the multidrug resistant strain H69AR and overexpression of periostin increases resistance of the sensitive strain H69 and hence periostin may be involved in SCLC chemoresistance.
ABSTRACT
Abstract: Introduction and aim. Hyponatremia is common in patients with decompensated cirrhosis and is associated with increased mortality. Tolvaptan, a vasopressor V2 receptor antagonist, can increase free wáter excretion, but its efficacy and safety in cirrhotic patients remain unclear. Material and methods. We studied the usage and safety of tolvaptan in cirrhotic patients in a real-life, non-randomized, multicenter prospective cohort study. Forty-nine cirrhotic patients with hyponatremia were treated with tolvaptan 15 mg daily, and 48 patients not treated with tolvaptan in the same period served as controls. Improvement in serum sodium level was defined as an increase in serum sodium from < 125 to ≥ 125 mmol/L or from 125-134 to ≥ 135 mmol/L on day 7. Results. Twenty-three (47%) patients in the tolvaptan group and 17 (35%) in the control group had normal serum sodium on day 7 (p = 0.25). Serum sodium improved in 30 (61%) patients in the tolvaptan group and 17 (35%) patients in the control group (p = 0.011). Adverse events occurred in 46-47% of patients in both groups, and tolvaptan was not associated with worsened liver function. No patient with normal serum sodium on day 7 died within 30 days of treatment, whereas 16% of those with persistent hyponatremia died (p = 0.0019). Conclusion. In conclusion, short-term tolvaptan treatment is safe and can improve serum sodium level in cirrhotic patients with hyponatremia. Normalization of serum sodium level is associated with better survival.